4D-110 is under clinical development by 4D Molecular Therapeutics and currently in Phase II for Choroideremia. According to GlobalData, Phase II drugs for Choroideremia does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the 4D-110 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
4D-110 is under development for the treatment of choroideremia. The therapy is administered through intravitreal route into retina. The therapy is based on vector evolution platform technology that uses AAV2 (Adeno-Associated Virus2) vector variant carrying a transgene encoding a codon-optimized human choroideremia (CHM) gene.
4D Molecular Therapeutics overview
4D Molecular Therapeutics is a gene therapy company that discovers and develops targeted and proprietary AAV gene therapy vectors and therapeutic products. The company’s pipeline products include 4D-125, 4D-110, 4D-150, 4D-135, 4D-310 and 4D-710. It has developed a technology platform, Therapeutic Vector Evolution that empowers to create customized gene delivery vehicles (novel AAV vectors) to deliver genes to any tissue or organ in the body. 4D Molecular Therapeutics develops pipeline products that targets therapeutic areas such as liver, retina, heart, brain, skeletal muscle, and lung, among others. The company works in partnership with F. Hoffmann-La Roche Ltd to design, develop and commercialize AAV products for use in ophthalmology indications. 4D Molecular Therapeutics is headquartered at Emeryville, California, the US.
For a complete picture of 4D-110’s drug-specific PTSR and LoA scores, buy the report here.